Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.

MLA

Farnier, Michel, et al. “Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia: An Open-Label Extension of the ODYSSEY Program.” Atherosclerosis (00219150), vol. 278, Nov. 2018, pp. 307–14. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2018.08.036.

APA

Farnier, M., Hovingh, G. K., Langslet, G., Dufour, R., Baccara-Dinet, M. T., Din-Bell, C., Manvelian, G., & Guyton, J. R. (2018). Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. Atherosclerosis (00219150), 278, 307–314. https://doi.org/10.1016/j.atherosclerosis.2018.08.036

Chicago

Farnier, Michel, G. Kees Hovingh, Gisle Langslet, Robert Dufour, Marie T. Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, and John R. Guyton. 2018. “Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia: An Open-Label Extension of the ODYSSEY Program.” Atherosclerosis (00219150) 278 (November): 307–14. doi:10.1016/j.atherosclerosis.2018.08.036.